Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2007 April;98(2) > Minerva Medica 2007 April;98(2):145-53

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  UPDATE ON VACCINES


Minerva Medica 2007 April;98(2):145-53

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Vaccines in development against avian influenza

Cox M. M. J.

Protein Sciences Corporation Meriden, CT, 06450, USA


PDF  


Avian influenza has become a high priority item for all public health authorities. An influenza pandemic is believed to be imminent. The only questions are what will be the causative agent and when will it happen. Recently, most attention has been directed to human cases of avian influenza caused by an H5N1 avian influenza virus. An effective vaccine will be needed to substantially reduce the impact of an influenza pandemic. Despite the fact that the current influenza vaccine manufacturing technology is not adequate to support vaccine production in the event of a pandemic influenza outbreak, most of the ongoing clinical development is occurring with vaccines made in embryonated chicken eggs. It is clear that innovative production technology is required. This review provides an update on the status of avian vaccine development. In addition available manufacturing technologies are presented, some of which could be more suitable to adequately respond to an emergency situation where billions of doses of vaccines would be required within a very short period of time. The review is concluded with some proposed areas of focus for pandemic vaccine preparedness.

top of page

Publication History

Cite this article as

Corresponding author e-mail